HAIR

We offer a variety of hair options for women and men ranging from basic cut and style to highlights, gloss, treatments and more.

Learn More

NAILS

From pedicure and manicures to acrylic nails and toes we have just the right option to help you look your best.

Learn More

SPA

Everyone deserves to be pampered. We can  help you relax and rejuvenate w/ a facial, massage or with one of our spa packages.

Learn More

But not in Norway until recently.

However, these phenolic substances only slightly inhibited the development of several bacteria causing meals poisoning and for that reason probably only have a small potential as bacteriostatic meals additives. In addition, researchers in The Norwegian University of Technology and Science in Trondheim were important collaborators. Cand.med.vet.. Chemical substance composition of chitosan influences antibacterial activity The polysaccharide chitosan includes a documented antibacterial effect.today announced that mature outcomes from a Phase 1/2 study analyzing CDX-011 in advanced stage breast cancers sufferers were presented at the 46th Annual Getting together with of the American Culture of Clinical Oncology . CDX-011 can be an experimental antibody-medication conjugate directed against glycoprotein NMB and linked to a potent cancers cell-killing medication, monomethyl-auristatin E . The results in triple unfavorable disease are especially encouraging, said Anthony Marucci, Chief and President Executive Officer of Celldex Therapeutics. A subset analysis utilizing a recently optimized diagnostic assay for GPNMB showed that sufferers with solid stromal or tumor cell expression of GPNMB could be most likely to react to CDX-011. Related StoriesViralytics enters into clinical trial collaboration contract with MSDMD Anderson research reveals why chemotherapy drugs not effective for most pancreatic cancer patientsNew findings reveal association between colorectal cancer tumor and melanoma drug treatment A trusted and marketable assay to detect a target antigen is crucial in the development of any targeted therapy, said Tom Davis, M.D., Chief Medical Officer of Celldex Therapeutics.